Adult B-Cell Acute Lymphoblastic Leukemia | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

B-cell acute lymphoblastic leukemia is a cancer that affects B-lymphocytes, which are white blood cells that grow in the soft center of bone called the bone marrow. About 75% of cases of acute lymphoblastic leukemia are of the B-cell type, while the rest are of the T-cell type. Total treatment usually lasts about two years, with the maintenance phase taking up most of that time. The intensity of treatment depends on the ALL subtype and other prognostic factors. ALL can spread around the brain and spinal cord.

Description

B-cell acute lymphoblastic leukemia is a cancer that affects B-lymphocytes, which are white blood cells that grow in the soft center of bone called the bone marrow. B lymphocytes must become cells that help fight infection, but in this disease, they turn into leukemia cells, which live longer than normal cells and multiply rapidly. They accumulate in the bone marrow and enter bloodstream. From there, they can spread to other organs in the body. A clonal population of lymphoid cells' abnormal proliferation and differentiation play a role in the pathogenesis of ALL. Genetic syndromes like Down syndrome, Fanconi anemia, Bloom syndrome, ataxia telangiectasia, and Nijmegen breakdown syndrome have been linked to studies in the paediatric population that predispose to a small percentage of ALL cases. Exposure to ionizing radiation, pesticides, specific solvents, or viruses like the Epstein-Barr virus and the Human Immunodeficiency Virus are additional risk factors. But most frequently, it develops in previously healthy people as a de novo malignancy.

Adult B-Cell Acute Lymphoblastic Leukemia (Epidemiology)

About 75% of cases of acute lymphoblastic leukemia are of the B-cell type, while the rest are of the T-cell type. Children 5 years of age and older have a higher risk of developing B-cell ALL. The overall complete response rate is greater than 95% in children and 60-85% in adults. Relapse occurs in 15% to 20% of children with B-cell ALL, and the prognosis becomes less favorable. Adult B-cell ALL has a recurrence rate of approximately 50% and is expected to carry a poor prognosis, with a median survival after relapse of less than 6 months. The incidence of ALL in the US is thought to be 1 point 6 per 100 000 people. According to the American Cancer Society, there were over 1400 ALL-related deaths in 2016 alone, with an estimated 6590 new cases being diagnosed. While dose-intensification strategies have significantly improved outcomes for pediatric patients, the prognosis for the elderly remains very poor. The incidence of ALL has a bimodal distribution, with the first peak occurring in childhood and a second peak occurring around the age of 50. Even though induction chemotherapy has a high rate of response, only 30-40% of adult patients with ALL will experience long-term remission.

Adult B-Cell Acute Lymphoblastic Leukemia -Current Market Size & Forecast Trends

The market for adult B-cell ALL therapies is a subset of the broader ALL therapeutics market. With the increasing adoption of targeted therapies such as Blinatumomab and CAR-T therapies like Tisagenlecleucel, the market for adult B-cell acute lymphoblastic leukemia (B-ALL) is expected to grow significantly, with an estimated value of around USD 3 billion in 2023 and a projected increase to about USD 5.84 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.8%.

The maintenance phase of the treatment typically takes up the majority of the two years that the total course of treatment lasts. The ALL subtype and other prognostic factors influence how aggressively the treatment is administered. The spinal cord and brain are both susceptible to ALL. CNS prophylaxis, a therapy that lowers the chance of leukemia spreading to the brain or spinal cord, is thus a crucial component of ALL treatment. Remission of leukemia (complete remission) is the aim of induction chemotherapy. Some treatment options may also include cyclophosphamide, L-asparaginase (or pegaspergase), high-dose methotrexate, or cytarabine (Ara-C) as part of the induction period, depending on the patient's prognostic factors. Targeted medications like imatinib (Gleevec) or dasatinib (Sprycil) are frequently added to treatment plans for all patients whose leukemia cells have the Philadelphia chromosome. Many of the same medications are used for induction but at lower doses for patients who are older (typically over 65) or have other serious health issues. A relatively brief course of chemotherapy using many of the same medications as induction therapy is typically the next step if leukemia enters remission. Normally, this takes several months. As a result of the intense nature of the treatment, these medications are typically administered in high doses. CNS prophylaxis is typically continued during this period. When a patient's leukemia cells carry the Philadelphia chromosome, targeted medications like imatinib are still used.

Report Highlights

Adult B-Cell Acute Lymphoblastic Leukemia - Current Market Trends

Adult B-Cell Acute Lymphoblastic Leukemia - Current & Forecasted Cases across the G8 Countries

Adult B-Cell Acute Lymphoblastic Leukemia - Market Opportunities and Sales Potential for Agents

Adult B-Cell Acute Lymphoblastic Leukemia - Patient-based Market Forecast to 2035

Adult B-Cell Acute Lymphoblastic Leukemia - Untapped Business Opportunities

Adult B-Cell Acute Lymphoblastic Leukemia - Product Positioning Vis-a-vis Competitors' Products

Adult B-Cell Acute Lymphoblastic Leukemia - KOLs Insight